Possible Association Between Vaspin Serum Levels and C-Reactive Protein in Obese Women with Polycystic Ovarian Syndrome

Aya Fawzi Talib; Shahad Sabah Khalid; Mohammed A. Abd

doi:10.22317/imj.v8i2.1286

Authors

Aya Fawzi Talib College of Pharmacy, Clinical Pharmacy Department, Uruk University, Baghdad, Iraq.
Shahad Sabah Khalid Department of Pharmacy, Al Nukhba University, Baghdad, Iraq.
Mohammed A. Abd Department of Pharmacy, Al Nukhba University, Baghdad, Iraq.

DOI:

https://doi.org/10.22317/imj.v8i2.1286

Keywords:

PCOS, Vaspin, C-reactive protein

Abstract

Objective

To investigate the levels of vaspin and C-reactive protein in women with polycystic ovarian syndrome (PCOS) and to assess their potential as diagnostic markers for the condition.

Methods

Ninety adult women were involved in the study, fifty of whom were obese women diagnosed with PCOS, while forty women served as healthy controls in an observational, case-control study. Blood samples were obtained from the participants, and all of them were questioned by the researcher. Vaspin and C-reactive protein serum levels were measured using enzyme-linked immunosorbent assay specialized kits.

Results

The study found a significant increase in vaspin and C-reactive protein serum levels in women in the PCOS group compared with controls, with P-values of <0.000 and 0.006, respectively. Vaspin serum level showed an AUC of 0.835, indicating it is a very good diagnostic marker for PCOS, while C-reactive protein had an AUC of 0.635, making it a moderate diagnostic marker for PCOS. The study also found a significant correlation between vaspin (pg/ml) and C-reactive protein (mg/l) with a P-value of 0.006.

Conclusion

The study found a significant increase in vaspin (pg/ml) and C-reactive protein (mg/l) serum levels in females with PCOS compared to control groups, with a significant positive correlation between the two biomarkers in PCOS. This suggests that vaspin and C-reactive protein may serve as useful diagnostic markers for PCOS.

References

Leon LIR, Mayrin J V. Polycystic ovarian disease (Stein-Leventhal syndrome). Stat Pearls [Internet] Stat Pearls Publ. 2018;

Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89(6):2548–56.

Klöting N, Kovacs P, Kern M, Heiker JT, Fasshauer M, Schön MR, et al. Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects. Diabetologia. 2011;54:1819–23.

Klöting N, Berndt J, Kralisch S, Kovacs P, Fasshauer M, Schön MR, et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun. 2006;339(1):430–6.

Jung CH, Lee MJ, Kang YM, Lee Y La, Yoon HK, Kang SW, et al. Vaspin inhibits cytokine-induced nuclear factor-kappa B activation and adhesion molecule expression via AMP-activated protein kinase activation in vascular endothelial cells. Cardiovasc Diabetol. 2014;13:1–11.

Marciniak A, Nawrocka-Rutkowska J, Brodowska A, Wiśniewska B, Starczewski A. Cardiovascular system diseases in patients with polycystic ovary syndrome-the role of inflammation process in this pathology and possibility of early diagnosis and prevention. Ann Agric Environ Med. 2016;23(4).

Rotterdam E. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25.

Giordano S. The 2008 Declaration of Helsinki: some reflections. J Med Ethics. 2010;36(10):598–603.

Akbarzadeh S, Ghasemi S, Kalantarhormozi M, Nabipour I, Abbasi F, Aminfar A, et al. Relationship among plasma adipokines, insulin and androgens level as well as biochemical glycemic and lipidemic markers with incidence of PCOS in women with normal BMI. Gynecol Endocrinol. 2012;28(7):521–4.

Cekmez F, Cekmez Y, Pirgon Ö, Canpolat FE, Aydinöz S, Ipcioglu OM, et al. Evaluation of new adipocytokines and insulin resistance in adolescents with polycystic ovary syndrome. Eur Cytokine Netw. 2011;22(1):32–7.

Shorakae S, Teede H, de Courten B, Lambert G, Boyle J, Moran LJ. The emerging role of chronic low-grade inflammation in the pathophysiology of polycystic ovary syndrome. In: Seminars in reproductive medicine. Thieme Medical Publishers; 2015. p. 257–69.

Escobar-Morreale HF, Luque-Ramírez M, González F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril. 2011;95(3):1048–58.

Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C, Aessopos A, Katsikis I, et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod. 2006;21(6):1426–31.